Advertisement

Strides Pharma Science Arm Gets USFDA Nod For HIV Treatment Drug

Follow The Hawk on Google News+ Follow

Advertisement


New Delhi: Drug firm Strides Pharma Science on Friday said its step-down wholly-owned subsidiary, Strides Pharma Global, has received approval from the US health regulator for Emtricitabine and Tenofovir Disoproxil Fumarate tablets, used to treat HIV.

The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Truvada tablets of Gilead Sciences.

Advertisement

Strides Pharma Global, Singapore, has received approval for Emtricitabine and Tenofovir Disoproxil Fumarate tablets in the strengths of 200 mg/300 mg from the United States Food and Drug Administration (USFDA), Strides Pharma Science said in a regulatory filing.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

Quoting IQVIA moving annual total (MAT) November 2020 data, Strides Pharma Science said the US market for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg is approximately USD 2.4 billion.

The product will be manufactured at the company''s facility at Bengaluru and will be marketed by Strides Pharma in the US market," the company added.

Advertisement

The company has 127 cumulative abbreviated new drug application (ANDA) filings with USFDA of which 95 ANDAs have been approved and 32 are pending approval.

Shares of Strides Pharma Science were trading 0.83 per cent higher at Rs 929 apiece on BSE. —PTI

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST